Overview

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give 1592U89 plus certain protease inhibitors (PIs) to HIV-infected patients who never have been treated with anti-HIV drugs. This study also examines how the body processes these drugs when they are given together.
Phase:
Phase 2
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Abacavir
Amprenavir
HIV Protease Inhibitors
Indinavir
Nelfinavir
Protease Inhibitors
Ritonavir
Saquinavir